47 results
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
research, development and commercialization goals.
If we fail to attract and retain senior management and key scientific personnel, our business may … for review of new molecular entity NDAs under its current PDUFA review goals.
In addition, a product may be eligible for accelerated approval. Drug
DRS
oc15g8b8
20 Oct 22
Draft registration statement
12:00am
DEF 14A
y5b9683rjfp0l3
25 Apr 22
Definitive proxy
5:28pm
10-K
5a6m vytxec
30 Mar 22
Annual report
7:40am
8-K
EX-99.1
ot2bxuk087 j6
30 Mar 22
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides
7:29am
8-K
EX-99.1
ymcbp2cpz86 4825z
10 Jan 22
Regulation FD Disclosure
7:01am
10-Q
gy6b4x7 by
17 Nov 21
Quarterly report
5:15pm
424B4
r1tyvrxlz9m70s qsf6o
12 Oct 21
Prospectus supplement with pricing info
4:11pm